CSI Market
Sign In | Register

Pharming Group N v (PHAR) Quarterly Income Statement

Quarterly · GAAP · USD millions
Access PHAR Annual Income Statement →
By examining income statement figures across successive periods, users can identify shifts in Pharming Group N v's profitability and expense structure.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
Q4 2025 		0 0 0 (Dec 31 2024)
Revenues
Revenue From Contracts With Customers376.13
Total Revenue375.63
Costs & Expenses
Cost of Goods and Services Sold45.50
Gross Profit330.63
Selling, Administration, Marketing79.96
Research and Development Expense100.37
Other Operating Expense / -Income123.97
Total operating costs including COS349.79
Operating income / -loss25.84
Net Interest (-)Expense / Income0.00
Other loss / -income13.00
Total costs & expenses362.79
Income & Taxes
Income / -loss before income taxes12.85
Income taxes expenses / -benefit10.31
Income after income taxes2.54
Net income / -loss of other equity0.00
Income / -loss from continuing operations2.54
Non-controlling interests-0.31
Net income / -loss2.54
Income / -loss to shareholder2.85
EBIT12.85
EBITD24.06
EBITDA24.06
Earnings Per Share
Basic EPS (excl. extra items)0.00
Basic Net EPS0.00
Diluted Net EPS0.00
4 historic quarters locked

Sign in to unlock the full Pharming Group N v income statement history.

Sign In Create Free Account

About PHAR Quarterly Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-Q filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

  • Source: SEC 10-Q filings
  • Filed with the SEC: n/a

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.